HomeSearch for 'Health'

Health - News and Articles about commonly prescribed drugs

Cardiovascular Well being Dangers Recognized With Diclofenac Use

Posted in News on 9th September 2018

September 07, 2018

Compared with NSAID non-initiators, diclofenac initiators had a 50% increased rate of MACE

Compared with NSAID non-initiators, diclofenac initiators had a 50% increased rate of MACE

Compared with traditional nonsteroidal anti-inflammatory drugs, the use of diclofenac increases the risk for major adverse cardiovascular events (MACE), according to a new study published in the BMJ.

To investigate the cardiovascular risks associated with diclofenac, researchers conducted a series of cohort studies mimicking the design criteria of a clinical trial. They compared the rates of MACE among diclofenac initiators and non-initiators or initiators of comparator drugs (ibuprofen, naproxen, acetaminophen). This method of analysis was chosen as current risk concerns make a standard clinical trial unethical.

The Danish National Patient Registry and the Danish National Prescription Registry were used to identify the study population and to identify drug use, respectively. Individuals were eligible if they were ≥18 years, had ≥1 year of continuous prescription records, and did not redeem NSAID prescriptions in the 12 month washout period before enrollment. Patients were followed until the first occurrence of a non-fatal endpoint, death, loss at follow-up, or 30 days of follow-up, whichever occurred first; this approach was applied to every month between January 1996 and December 2016. Data from these trials (N=252) were then pooled into 1 model for analysis.

Related Articles

Results showed that within 30 days, MACE occurred among 1465 (0.10%; N=1,370,832) diclofenac initiators, 2912 (0.07%; N=3,878,454) ibuprofen initiators, 205 (0.07%; N=291,490) naproxen initiators, 967 (0.13%; N=764,781) acetaminophen initiators, and 898 (0.07%; N=1,303,209) NSAID non-initiators.

Compared with NSAID non-initiators, diclofenac initiators had a 50% increased rate of MACE (incidence rate ratio [IRR] 1.5, 95% CI 1.4 to 1.7). The adverse event rate for diclofenac initiators increased for all individual outcomes compared with NSAID non-initiators: 1.2-fold for atrial fibrillation/flutter, 1.6-fold for ischemic stroke, 1.7-fold for heart failure, 1.9-fold for myocardial infarction, and 1.7-fold for cardiac death. In addition, diclofenac initiators had a 20% increased rate of MACE compared with ibuprofen and acetaminophen initiators (both IRR 1.2, 95% CI 1.1 to 1.3) and a 30% increased rate compared with naproxen initiators (IRR 1.3, 95% CI 1.1 to 1.5).

With regard to upper gastrointestinal bleeding, diclofenac initiation increased the risk at 30 days by 2.5-fold compared with ibuprofen (IRR 2.5, 2.1 to 3.1) or acetaminophen (IRR 2.4, 2.0 to 2.9) initiation and by 4.5-fold compared with no initiation (IRR 4.4, 3.5 to 5.5).

“It is time to acknowledge the potential health risk of diclofenac and to reduce its use,” write the authors in their conclusion. “Considering its cardiovascular and gastrointestinal risks, […] there is little justification to initiate diclofenac treatment before other traditional NSAIDs.”

For more information visit BMJ.com.

Scroll down to see the next article

Atlantic Well being System begins enrolling sufferers in 4 pancreatic most cancers scientific trials

Posted in News on 1st July 2018

Atlantic Well being System is now enrolling sufferers in 4 pancreatic most cancers scientific trials. Angela Alistar, MD, a nationally identified skilled on pancreatic most cancers, is serving as nationwide Principal Investigator (PI) on the primary trial and as native PI on three different trials. As well as, Dr. Alistar will function a nationwide and native PI on three further scientific research open to enrollment later this yr.

“We’re lucky to have the ability to provide these research to individuals with this difficult-to-treat, aggressive most cancers,” mentioned Dr. Alistar, who serves as director of GI medical oncology on the Carol G. Simon Most cancers Heart of Morristown Medical Heart, Atlantic Well being System. “Our pancreatic most cancers program is exclusive, and our means to offer entry to those scientific trials is one necessary side of our uniqueness. New and simpler remedies are desperately wanted.”

5-year survival charges for pancreatic most cancers are low, even when caught early. In 2016, pancreatic most cancers moved from the fourth main explanation for cancer-related deaths within the U.S. to the third, surpassing breast most cancers.

“Dr. Alistar is a number one determine in GI most cancers analysis and therapy, and she or he has considerably enhanced our means to take care of our sufferers,” mentioned Eric Whitman, MD, medical director, Atlantic Well being System Most cancers Care. “She has expanded Atlantic Well being System’s means to supply participation in scientific trials for pancreatic most cancers and different gastrointestinal malignancies, in addition to the newest remedies, reminiscent of those who work with sufferers’ immune programs to destroy most cancers cells.”

Pancreatic most cancers research which are at present enrolling sufferers embody:

  • Part 1 Research of CPI-613 in Mixture with Gemcitabine and Nab-Paclitaxel for Sufferers with Regionally Superior or Metastatic Pancreatic Most cancers. It is a single arm, open-label examine of CPI-613, a first-in-class drug with a novel mode of motion, together with chemotherapeutic brokers gemcitabine and nab-paclitaxel. The examine, which is funded by Raphael Prescribed drugs, Inc., is designed for sufferers with regionally superior or metastatic pancreatic most cancers by no means handled with systemic chemotherapy. Atlantic Well being System is the one program on this planet to supply this promising examine. Dr. Alistar led earlier research of this promising drug with pancreatic most cancers exercise, which have been offered at main worldwide scientific conferences and revealed in The Lancet Oncology. NCT03435289
  • Part 2 Research of the Antioxidant BPM31510 (Ubidecarenone, or CoQ10) Nanosuspension Injection Administered Intravenously With or With out Gemcitabine as 2nd/third Line Remedy in Superior Pancreatic Most cancers Sufferers. It is a Part 2 multicenter, open-label, non-randomized examine to look at the security and effectiveness of BPM31510 administered as a 144-hour steady intravenous infusion by itself or together with gemcitabine in superior pancreatic most cancers sufferers as a 2nd / third line remedy. The examine is sponsored by Berg LLC and is open at seven complete websites within the U.S. Atlantic Well being System is the one examine web site in New Jersey and New York. NCT02650804
  • An SU2C Catalyst® Randomized Part II Trial of the PD1 Inhibitor Pembrolizumab With or With out Vitamin D Receptor Agonist Paricalcitol in Sufferers With Stage IV Pancreatic Most cancers Who Have Been Positioned in Finest Potential Response. Chemotherapy regimens for pancreatic most cancers can now stabilize a affected person’s most cancers and/or place some sufferers in remission or partial remission. The problem now’s to search out choices for upkeep therapies that can enhance survival and permit continued advantages with minimal toxicities and inconvenience to sufferers. This examine will decide the results of immunotherapy as one attainable upkeep routine. The examine is being carried out to find out the results that pembrolizumab with or with out the addition of paricalcitol might have on pancreatic most cancers. Half of the sufferers might be randomized to obtain pembrolizumab (Keytruda?, a monoclonal antibody) plus paricalcitol (artificial Vitamin D) and half to obtain pembrolizumab plus placebo. This examine is sponsored by The Translational Genomics Analysis Institute. Atlantic Well being System’s Morristown Medical Heart is the one heart on the East Coast that has this examine open. NCT03331562
  • Preoperative Prolonged Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Remedy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas. The aim of this examine is to find out the very best sequence of chemotherapy and chemoradiotherapy previous to surgical procedure. This examine is sponsored by Alliance and is open nationwide. NCT02839343 Every examine has particular standards for participation.

Supply:

https://www.atlantichealth.org/about-us/stay-connected/information/press-releases/2018/june18-alistar-pancreatic-cancer-clinical-trials.html

Posted in: Drug Trial Information | Medical Situation Information

Tags: Antibody, Antioxidant, Breast Most cancers, Most cancers, Catalyst, Chemoradiotherapy, Chemotherapy, Youngsters, Gemcitabine, Genomics, Well being Care, Healthcare, Dwelling Care, Hospice, Hospital, Immunotherapy, Monoclonal Antibody, Oncology, Paclitaxel, Pancreas, Pancreatic Most cancers, Prescribed drugs, Placebo, Radiation Remedy, Receptor, Analysis, Surgical procedure, Vitamin, Vitamin D

How does lisinopril have an effect on kidney operate ? | Greatest Well being Channel ..!

Posted in Vasotec on 24th June 2018

What are some coronary heart medicines ? | Well being FAQS | It is All about your well being

Posted in Accupril on 2nd June 2018

How does carvedilol work in coronary heart failure ? | Well being FAQS for Higher Life

Posted in Vasotec on 15th March 2018